Filing Flows

Filing Flows › Health Care › Elite Pharmaceuticals (ELTP)

Elite Pharmaceuticals (ELTP) earnings and revenue breakdown

Latest: Q1 FY27 · 10-Q filed Aug 13, 2026 · Elite Pharmaceuticals (ELTP) Q1 FY27 earnings results →

Q1 FY27 Revenue down 20% year over year to $32.4M · 18¢ of every $1 of revenue kept as net profit · operating margin 23.3%

Elite Pharmaceuticals made $32.4M in Q1 FY27 (-20% Y/Y): Abbreviated New Drug Applications Revenue $32.1M, Licensing $221K. Operating margin 23.3%, net earnings $5.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.

Revenue$32.4M
Year over year-20%
Operating margin23.3%
Net earnings$5.9M
Operating cash flow$10.1M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $32.4M in Q1 FY27, down 20% year over year and down 21% from the previous quarter. Direct Sales to Wholesalers was the largest line at 51% of revenue. Indirect Sales to Wholesalers lost $5.0M year over year (down 24%), 64% of the total change.

Gross margin was 41.7%, down 26.0 points from Q1 FY26. Operating profit was $7.5M, a 23.3% margin (down 30.7 points year over year). Operating expenses grew 8% against a revenue fall of 20%. The fastest-growing cost line was Research & development (+21%). Net earnings were $5.9M. The effective tax rate was 23.4%.

Operating cash flow was $10.1M (down 32% year over year), 170% of net earnings. Non-cash charges added back $253K of depreciation and $28K of share-based compensation. Working capital and other items added $3.9M. Capital expenditures of $809K left free cash flow of $9.3M.

Quarterly history

Elite Pharmaceuticals revenue by quarterElite Pharmaceuticals revenue by quarter$14.4MQ3 FY25$32.0MQ4 FY25$40.2MQ1 FY26$36.3MQ2 FY26$31.6MQ3 FY26$40.7MQ4 FY26$32.4MQ1 FY27
Elite Pharmaceuticals net earnings by quarterElite Pharmaceuticals net earnings by quarter−$10.9MQ3 FY25$17.0MQ4 FY25−$5.9MQ1 FY26$13.7MQ2 FY26$18.6MQ3 FY26$18.5MQ4 FY26$5.9MQ1 FY27
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q1 FY2710-QAug 13, 2026$32.4M-20%23.3%$5.9M$10.1M
Q4 FY2610-KJun 29, 2026$40.7M+27%25.0%$18.5M$9.1M
Q3 FY2610-QFeb 17, 2026$31.6M+120%28.5%$18.6M−$5.3M
Q2 FY2610-QNov 14, 2025$36.3M+92%22.6%$13.7M$5.1M
Q1 FY2610-QAug 14, 2025$40.2M+114%54.0%−$5.9M$14.8M
Q4 FY2510-KJun 30, 2025$32.0M+78%34.9%$17.0M$3.9M
Q3 FY2510-QFeb 13, 2025$14.4M-8%7.6%−$10.9M−$1.1M

Charts

Elite Pharmaceuticals: revenue growth, year over year and quarter over quarterElite Pharmaceuticals: revenue growth, year over year and quarter over quarterY/YQ/Q-8%Q3 FY25+78%+123%Q4 FY25+114%+26%Q1 FY26+92%-10%Q2 FY26+120%-13%Q3 FY26+27%+29%Q4 FY26-20%-21%Q1 FY27
Latest (Q1 FY27): Y/Y -20%, Q/Q -21%.
Elite Pharmaceuticals: where the cash came from (+) and went (−), TTM to Q1 FY27Elite Pharmaceuticals: where the cash came from (+) and went (−), TTM to Q1 FY27Operating cash flow$19.0MCash drawn (+) / kept (−)−$17.2MCapital spending−$1.5MNet borrowing (+) / repaid (−)−$384KOther financing$78K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Elite Pharmaceuticals: profit against cash, quarter by quarterElite Pharmaceuticals: profit against cash, quarter by quarterNet incomeOperating cash flow−$11.0M$1.5MQ2 FY25−$10.9M−$1.1MQ3 FY25$17.0M$3.9MQ4 FY25−$5.9M$14.8MQ1 FY26$13.7M$5.1MQ2 FY26$18.6M−$5.3MQ3 FY26$18.5M$9.1MQ4 FY26$5.9M$10.1MQ1 FY27
Latest (Q1 FY27): Net income $5.9M, Operating cash flow $10.1M.
Elite Pharmaceuticals: diluted shares by fiscal yearElite Pharmaceuticals: diluted shares by fiscal year943MFY211.01BFY221.01BFY231.02BFY241.07BFY251.14BFY26
+20.7% since FY21: more shares outstanding (issuance, stock pay).
Elite Pharmaceuticals in its industry: growth against margin (225 companies, SIC 2834)Elite Pharmaceuticals in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXENTATNXPOCULASMBWVEAPMDBFRIABEOSTOKLXRXCAPRIDYANKTRZOMDFINBPJANXSBFMGOSSETSTRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXBFRGSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMELTP (-20%, 23%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Elite Pharmaceuticals

Elite Pharmaceuticals, Inc., a Nevada corporation (the “Company”, “Elite”, “Elite Pharmaceuticals”, the “registrant”, “we”, “us” or “our”) was incorporated on October 1, 1997 under the laws of the State of Delaware, and its wholly-owned subsidiary, Elite Laboratories, Inc. (“Elite Labs”), was incorporated on August 23, 1990 under the laws of the State of Delaware. On January 5, 2012, Elite Pharmaceuticals was reincorporated under the laws of the State of Nevada. We are a specialty pharmaceutical company principally engaged in the development and manufacture of oral, controlled-release products, and the manufacture of generic pharmaceuticals. Our strategy includes developing generic versions of controlled-release drug products with high barriers to entry.

In its own words, from its 10-K, filed Jun 29, 2026.

Elite Pharmaceuticals against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -20% against the peers' median +7%. Operating margin: 23.3% against the peers' median 23.3%.

CompanyQuarterRevenueY/YOp. margin
ELTP Elite PharmaceuticalsQ1 FY27$32.4M-20%23.3%
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: Elite Pharmaceuticals 10-Q on SEC EDGAR · CIK 1053369 · Pharmaceutical Preparations

13F: who owns ELTP and who is buying

Largest holders of ELTP (13F)Largest holders of ELTP (13F)Kelleher Financial Advisors$365
Funds' net buying of ELTP by quarter (13F)Funds' net buying of ELTP by quarter (13F)$2K2025-03$02025-06$3202025-09−$3K2025-12$02026-03$1822026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on ELTP

History

Every quarter: Q1 FY27 results · Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results

Compare ELTP with

中文版：Elite Pharmaceuticals（ELTP）财报

Español · Français